NRX Pharmaceuticals (NRXP) EBT Margin (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly EBT Margin of 465.36% for Q1 2026, up 9.33% quarter-over-quarter from 513.26% in Q4 2025.

NRX Pharmaceuticals (NRXP) EBT Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported EBT Margin for 2 consecutive years, with 465.36% the latest figure, recorded in Q1 2026.

In Q1 2026, EBT Margin changed N/A year-over-year to 465.36%; the TTM figure through Mar 2026 stood at 800.81% (changed N/A YoY), while the FY2025 annual figure was 5617.67%, changed N/A from the prior year.
EBT Margin climbed to 465.36% in Q1 2026 per NRXP's latest filing, from 513.26% in the prior quarter.
Across five years, EBT Margin topped out at 465.36% in Q1 2026 and bottomed at 2105.5% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.81 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.52 Bn	78.52 Bn	3.93 Bn	35.61%
3	Argenx Se	65.30 Bn	60.11 Bn	1.37 Bn	35.71%
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.77 Bn	28.46 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn	-25.06%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	12.09%
10	NRX Pharmaceuticals	132.83 Mn	106.13 Mn	426,000.00	-612.08%

Download Data